TTM
$2.34
YoY change
+47.2%
5Y CAGR
+10.5%
Peak year (2025)
$2.09
Latest annual
$2.09
EPS (Diluted) history chart for DexCom (DXCM) from 2000 to 2025
Latest: $2.09
EPS (Diluted) growth chart for DexCom (DXCM) from 2000 to 2025
Latest: +47.2%
EPS (Diluted) history table for DexCom (DXCM) from 2000 to 2025
| 2025 | $2.09 | +47.2% | +$0.67 | ||
| 2024 | $1.42 | +9.2% | +$0.12 | ||
| 2023 | $1.30 | +62.5% | +$0.50 | ||
| 2022 | $0.80 | +56.9% | +$0.29 | ||
| 2021 | $0.51 | -59.8% | −$0.76 | ||
| 2020 | $1.27 | +370.4% | +$1.00 | ||
| 2019 | $0.27 | -175.0% | +$0.63 | ||
| 2018 | −$0.36 | +140.0% | −$0.21 | ||
| 2017 | −$0.15 | -25.0% | +$0.05 | ||
| 2016 | −$0.20 | +11.1% | −$0.02 | ||
| 2015 | −$0.18 | +141.6% | −$0.11 | ||
| 2014 | −$0.07 | -25.5% | +$0.03 | ||
| 2013 | −$0.10 | -50.0% | +$0.10 | ||
| 2012 | −$0.20 | +17.6% | −$0.03 | ||
| 2011 | −$0.17 | -29.2% | +$0.07 | ||
| 2010 | −$0.24 | -20.0% | +$0.06 | ||
| 2009 | −$0.30 | -36.2% | +$0.17 | ||
| 2008 | −$0.47 | +14.6% | −$0.06 | ||
| 2007 | −$0.41 | -4.7% | +$0.02 | ||
| 2006 | −$0.43 | +4.9% | −$0.02 | ||
| 2005 | −$0.41 | -73.2% | +$1.12 | ||
| 2004 | −$1.53 | +34.2% | −$0.39 | ||
| 2003 | −$1.14 | +21.3% | −$0.20 | ||
| 2002 | −$0.94 | +13.3% | −$0.11 | ||
| 2001 | −$0.83 | +45.6% | −$0.26 | ||
| 2000 | −$0.57 | — | — |
- 2025$2.09+47.2%
- 2024$1.42+9.2%
- 2023$1.30+62.5%
- 2022$0.80+56.9%
- 2021$0.51-59.8%
- 2020$1.27+370.4%
- 2019$0.27-175.0%
- 2018−$0.36+140.0%
- 2017−$0.15-25.0%
- 2016−$0.20+11.1%
- 2015−$0.18+141.6%
- 2014−$0.07-25.5%
- 2013−$0.10-50.0%
- 2012−$0.20+17.6%
- 2011−$0.17-29.2%
- 2010−$0.24-20.0%
- 2009−$0.30-36.2%
- 2008−$0.47+14.6%
- 2007−$0.41-4.7%
- 2006−$0.43+4.9%
- 2005−$0.41-73.2%
- 2004−$1.53+34.2%
- 2003−$1.14+21.3%
- 2002−$0.94+13.3%
- 2001−$0.83+45.6%
- 2000−$0.57—
EPS (Diluted) values are taken from DexCom's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's current diluted EPS (TTM) is $2.34. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, DexCom (DXCM) reported diluted EPS of $2.09 – surged 47.2% year-over-year.
Through 2020–2025 (5 years), DexCom diluted EPS delivered a +10.5% annualised rate; sustaining 4 straight years of year-over-year growth.
The highest annual diluted EPS of $2.09 was reported in 2025. The lowest in the available history was −$1.53 in 2004.
DexCom EPS (Diluted) by Year
DexCom EPS (Diluted) 2025: $2.09
2025's diluted EPS for DexCom came in at $2.09, surged 47.2% from 2024. This figure represents the highest annual value in the available history.
DexCom EPS (Diluted) 2024: $1.42
DexCom posted diluted EPS of $1.42 in 2024, grew 9.2% from 2023.
DexCom EPS (Diluted) 2023: $1.30
In 2023, DexCom reported diluted EPS of $1.30, surged 62.5% from 2022.
DexCom EPS (Diluted) 2022: $0.80
DexCom diluted EPS in 2022 was $0.80, surged 56.9% from 2021.
DexCom EPS (Diluted) 2021: $0.51
DexCom diluted EPS in 2021 was $0.51.
See more financial history for DexCom (DXCM). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of DexCom (DXCM), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
DexCom (DXCM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation